Literature DB >> 25395147

Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection.

Takahiro Nishio1, Etsuro Hatano, Takaki Sakurai, Kojiro Taura, Masayuki Okuno, Yosuke Kasai, Satoru Seo, Kentaro Yasuchika, Akira Mori, Toshimi Kaido, Shinji Uemoto.   

Abstract

BACKGROUND: Although the prevalence of non-B non-C hepatocellular carcinoma (NBNC HCC) has increased, its clinicopathologic characteristics remain unclear.
METHODS: We retrospectively analyzed 518 HCC patients who underwent hepatic resection. Hepatitis B surface antigen- and hepatitis C antibody-negative patients were categorized into the NBNC HCC group (n = 145); others were categorized into the hepatitis B or C HCC (BC HCC) group (n = 373). We subdivided the etiologies of NBNC HCC according to alcohol intake and presence of steatosis.
RESULTS: NBNC HCC was associated with nonalcoholic fatty liver disease (NAFLD) (13.1 %), fatty liver disease with moderate alcohol intake (9.0 %), alcoholic liver disease (ALD) (29.7 %), cryptogenic disease (44.1 %), and other known etiologies (4.1 %). The prevalence of obesity, diabetes mellitus, and hypertension was higher and hepatic function was better in the NBNC HCC group, which had significantly larger tumors than the BC HCC group. The entire NBNC HCC group displayed similar overall and disease-free survival as the BC HCC group. Among the subdivisions, NAFLD-associated HCC patients had significantly better disease-free survival than ALD-associated HCC and BC HCC patients. Microvascular invasion (hazard ratio [HR] 2.30; 95 % confidence interval [CI] 1.33-3.96) and steatosis area <5 % of noncancerous region (HR 2.13; 95 % CI 1.21-3.93) were associated with disease-free survival in NBNC HCC patients.
CONCLUSIONS: The prognosis of NBNC HCC was similar to that of BC HCC. Among NBNC HCC patients, NAFLD-associated HCC patients had a relatively low recurrence risk. Absence of steatosis in hepatic parenchyma had a significant impact on disease-free survival in NBNC HCC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25395147     DOI: 10.1245/s10434-014-4181-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma.

Authors:  Jian Zheng; Deborah Kuk; Mithat Gönen; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Ronald P DeMatteo
Journal:  Ann Surg Oncol       Date:  2016-12-05       Impact factor: 5.344

2.  Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas.

Authors:  Masakazu Hashimoto; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Michinori Hamaoka; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2017-05-22       Impact factor: 3.445

3.  Repeated-measures implication of hepatocellular carcinoma biomarkers in living donor liver transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Kuang-Den Chen; Li-Wen Hsu; Chia-Yun Lai; Ching-Yin Huang; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

4.  Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma.

Authors:  Kongying Lin; Qizhen Huang; Yuting Huo; Jianxing Zeng; Zongren Ding; Pengfei Guo; Zhenwei Chen; Yongyi Zeng; Jingfeng Liu
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

5.  Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.

Authors:  Lei Liu; Si Xie; Yu-Xian Teng; Zhu-Jian Deng; Kang Chen; Hao-Tian Liu; Rong-Rui Huo; Xiu-Mei Liang; Ping-Ping Guo; Da-Long Yang; Liang Ma; Bang-De Xiang; Le-Qun Li; Jian-Hong Zhong
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

6.  Nonalcoholic non-virus-related hepatocellular carcinoma arising from nonsteatotic liver: Clinical and pathological features.

Authors:  Yasuyuki Shigematsu; Hiroaki Kanda; Gulanbar Amori; Yu Takahashi; Yutaka Takazawa; Kentaro Inamura
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.